title: Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement.
abstract: BACKGROUND
  Sudden cardiac death (SCD) is the most lethal manifestation of heart disease. In an Indian study the SCDs contribute about 10% of the total mortality and SCD post ST elevation myocardial infarction (MI) constitutes for about half of total deaths.
  
  
  OBJECTIVE
  Given the limitations of existing therapy there is a need for an effective, easy to use, broadly applicable and affordable intervention to prevent SCD post MI. Leading cardiologists from all over India came together to discuss the potential role of n-3 acid ethyl esters (90%) of eicosapentaenoic acid (EPA) 460 mg & docosahexaenoic acid (DHA) 380 mg in the management of post MI patients and those with hypertriglyceridemia.
  
  
  CONCLUSIONS
  Highly purified & concentrated omega-3 ethyl esters (90%) of EPA (460 mg) & DHA (380 mg) has clinically proven benefits in improving post MI outcomes (significant 15% risk reduction for all-cause mortality, 20% risk reduction for CVD and 45% risk reduction in SCD in GISSI-Prevenzione trial) and in reducing hypertriglyceridemia, and hence, represent an interesting option adding to the treatment armamentarium in the secondary prevention after MI based on its anti-arrhythmogenic effects and also in reducing hypertriglyceridemia.
authors.affiliation: Kokilaben Dhirubhai Ambani Hospital, Mumbai, India. jjdalal@hotmail.com
authors.forename: J J
authors.initials: JJ
authors.lastname: Dalal
authors.forename: R R
authors.initials: RR
authors.lastname: Kasliwal
authors.forename: A L
authors.initials: AL
authors.lastname: Dutta
authors.forename: J P S
authors.initials: JP
authors.lastname: Sawhney
authors.forename: S S
authors.initials: SS
authors.lastname: Iyengar
authors.forename: S
authors.initials: S
authors.lastname: Dani
authors.forename: N
authors.initials: N
authors.lastname: Desai
authors.forename: I
authors.initials: I
authors.lastname: Sathyamurthy
authors.forename: D
authors.initials: D
authors.lastname: Rao
authors.forename: A
authors.initials: A
authors.lastname: Menon
authors.forename: A
authors.initials: A
authors.lastname: Dasbiswas
authors.forename: G S
authors.initials: GS
authors.lastname: Wander
authors.forename: M
authors.initials: M
authors.lastname: Chadha
authors.forename: M S
authors.initials: MS
authors.lastname: Hiremath
authors.forename: D G
authors.initials: DG
authors.lastname: Roy
authors.forename: V
authors.initials: V
authors.lastname: Gupta
authors.forename: N
authors.initials: N
authors.lastname: Shivakadaksham
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control*; D004281:Docosahexaenoic Acids / Q000627:therapeutic use*; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use*; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007194:India / Q000453:epidemiology; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D011314:Preventive Health Services; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D004338:Drug Combinations; D000960:Hypolipidemic Agents; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; C405603:Omacor